https://interactions.guidetherapeutiquevih.com/en/interaction-details?id=8199
https://interactions.guidetherapeutiquevih.com/en/interaction-details?id=8199
No pharmaceutical opinion available for this interaction.
Phenobarbital may induce the metabolism (UGT) and decrease the plasma concentration of Raltegravir.
Possible decrease of clinical efficacy.
Association not recommended and more particularly with raltegravir HD 1200 mg QD.
Choose another antiretroviral therapy.
If this combination is used, increase the dose of raltegravir to 800 mg BID.
Monitor for signs and symptoms of therapeutic failure.
See comments for further details.
–
–
If possible, consider an alternative.
As clinically indicated : brivaracetam, clobazam, clonazepam, ethosuximide, gabapentin, lacosamide, lamotrigine, levetiracetam, pregabalin, rufinamide, stiripentol, tiagabine, topiramate, valproic acid, vigabatrin, zonisamide.
–
Raltegravir plasma level
Viral Load
CD4+
–
Ref #2152 : Coadministration has not been studied. The product monograph does not suggest dose adjustment with raltegravir and anticonvulsants. However, it suggests with rifampin (potent UGT inducer) an increase in the dose of raltegravir to 800 mg BID.
See raltegravir + rifampin.